Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AD 17002

Next Previous
Drug Profile

AD 17002

Alternative Names: AD17002; AD17002-SC; Airway allergy immunotherapy - Advagene BioPharma; DCB 07010; LTh(αK)

Latest Information Update: 17 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advagene Biopharma
  • Developer Advagene Biopharma; Taipei Medical University
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Asthma
  • Phase I/II Allergic rhinitis

Most Recent Events

  • 28 Feb 2025 Efficacy and adverse events data from a phase II trial in Asthma presented at the 2025 Annual Meeting of the American Academy of Allergy, Asthma and Immunology/World Allergy Organization Joint Congress, 2025 (AAAAI-WAO-2025)
  • 27 Nov 2023 Phase-II clinical trials in Asthma (In adults, In the elderly) in Taiwan (Intranasal) (NCT05985694)
  • 28 May 2023 Advagene Biopharma completes a phase II trial in COVID-2019 infections in Taiwan (Intranasal) (NCT05069610)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top